カテゴリー： Market Monitor Global, 世界, 医療/バイオ

乳がん標的療法の世界市場見通し2023年-2029年

◆英語タイトル：Targeted Therapy for Breast Cancer Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8697 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：67 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Targeted Therapy for Breast Cancer Market 調査レポートは次の情報を含め、グローバルにおけるの乳がん標的療法市場規模と予測を収録しています。・世界の乳がん標的療法市場：売上、2018年-2023年、2024年-2029年
・世界の乳がん標的療法市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の乳がん標的療法市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ブランド医薬品」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

乳がん標的療法のグローバル主要企業は、Eli Lilly and Company、 Roche、 Merck & Co.、 Novartis、 Pfizer、 Merck KGaA、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Gilead Sciencesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、乳がん標的療法のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の乳がん標的療法市場：タイプ別、2018年-2023年、2024年-2029年
世界の乳がん標的療法市場：タイプ別市場シェア、2022年
・ブランド医薬品、ジェネリック医薬品

世界の乳がん標的療法市場：用途別、2018年-2023年、2024年-2029年
世界の乳がん標的療法市場：用途別市場シェア、2022年
・病院、小売薬局、その他

世界の乳がん標的療法市場：地域・国別、2018年-2023年、2024年-2029年
世界の乳がん標的療法市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における乳がん標的療法のグローバル売上、2018年-2023年
・主要企業における乳がん標的療法のグローバル売上シェア、2022年
・主要企業における乳がん標的療法のグローバル販売量、2018年-2023年
・主要企業における乳がん標的療法のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Eli Lilly and Company、 Roche、 Merck & Co.、 Novartis、 Pfizer、 Merck KGaA、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Gilead Sciences

*************************************************************

・調査・分析レポートの概要
乳がん標的療法市場の定義
市場セグメント
世界の乳がん標的療法市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の乳がん標的療法市場規模
世界の乳がん標的療法市場規模：2022年 VS 2029年
世界の乳がん標的療法市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの乳がん標的療法の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の乳がん標的療法製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：ブランド医薬品、ジェネリック医薬品
乳がん標的療法のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、小売薬局、その他
乳がん標的療法の用途別グローバル売上・予測

・地域別市場分析
地域別乳がん標的療法市場規模 2022年と2029年
地域別乳がん標的療法売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Eli Lilly and Company、 Roche、 Merck & Co.、 Novartis、 Pfizer、 Merck KGaA、 Astellas、 Janssen Biotech、 Bristol-Myers Squibb、 Gilead Sciences
...

Breast cancer is a disease in which cells in the breast grow out of control. There are different kinds of breast cancer.
This report aims to provide a comprehensive presentation of the global market for Targeted Therapy for Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Therapy for Breast Cancer. This report contains market size and forecasts of Targeted Therapy for Breast Cancer in global, including the following market information:
Global Targeted Therapy for Breast Cancer Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Targeted Therapy for Breast Cancer market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Brand Drugs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Targeted Therapy for Breast Cancer include Eli Lilly and Company, Roche, Merck & Co., Novartis, Pfizer, Merck KGaA, Astellas, Janssen Biotech and Bristol-Myers Squibb, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Targeted Therapy for Breast Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Targeted Therapy for Breast Cancer Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Targeted Therapy for Breast Cancer Market Segment Percentages, by Type, 2022 (%)
Brand Drugs
Generic Drug
Global Targeted Therapy for Breast Cancer Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Targeted Therapy for Breast Cancer Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Other
Global Targeted Therapy for Breast Cancer Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Targeted Therapy for Breast Cancer Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Targeted Therapy for Breast Cancer revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Targeted Therapy for Breast Cancer revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eli Lilly and Company
Roche
Merck & Co.
Novartis
Pfizer
Merck KGaA
Astellas
Janssen Biotech
Bristol-Myers Squibb
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Targeted Therapy for Breast Cancer, market overview.
Chapter 2: Global Targeted Therapy for Breast Cancer market size in revenue.
Chapter 3: Detailed analysis of Targeted Therapy for Breast Cancer company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Targeted Therapy for Breast Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Targeted Therapy for Breast Cancer Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Targeted Therapy for Breast Cancer Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Targeted Therapy for Breast Cancer Overall Market Size
2.1 Global Targeted Therapy for Breast Cancer Market Size: 2022 VS 2029
2.2 Global Targeted Therapy for Breast Cancer Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Targeted Therapy for Breast Cancer Players in Global Market
3.2 Top Global Targeted Therapy for Breast Cancer Companies Ranked by Revenue
3.3 Global Targeted Therapy for Breast Cancer Revenue by Companies
3.4 Top 3 and Top 5 Targeted Therapy for Breast Cancer Companies in Global Market, by Revenue in 2022
3.5 Global Companies Targeted Therapy for Breast Cancer Product Type
3.6 Tier 1, Tier 2 and Tier 3 Targeted Therapy for Breast Cancer Players in Global Market
3.6.1 List of Global Tier 1 Targeted Therapy for Breast Cancer Companies
3.6.2 List of Global Tier 2 and Tier 3 Targeted Therapy for Breast Cancer Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Targeted Therapy for Breast Cancer Market Size Markets, 2022 & 2029
4.1.2 Brand Drugs
4.1.3 Generic Drug
4.2 By Type – Global Targeted Therapy for Breast Cancer Revenue & Forecasts
4.2.1 By Type – Global Targeted Therapy for Breast Cancer Revenue, 2018-2023
4.2.2 By Type – Global Targeted Therapy for Breast Cancer Revenue, 2024-2029
4.2.3 By Type – Global Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Targeted Therapy for Breast Cancer Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Targeted Therapy for Breast Cancer Revenue & Forecasts
5.2.1 By Application – Global Targeted Therapy for Breast Cancer Revenue, 2018-2023
5.2.2 By Application – Global Targeted Therapy for Breast Cancer Revenue, 2024-2029
5.2.3 By Application – Global Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Targeted Therapy for Breast Cancer Market Size, 2022 & 2029
6.2 By Region – Global Targeted Therapy for Breast Cancer Revenue & Forecasts
6.2.1 By Region – Global Targeted Therapy for Breast Cancer Revenue, 2018-2023
6.2.2 By Region – Global Targeted Therapy for Breast Cancer Revenue, 2024-2029
6.2.3 By Region – Global Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Targeted Therapy for Breast Cancer Revenue, 2018-2029
6.3.2 US Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.3.3 Canada Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.3.4 Mexico Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Targeted Therapy for Breast Cancer Revenue, 2018-2029
6.4.2 Germany Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.4.3 France Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.4.4 U.K. Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.4.5 Italy Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.4.6 Russia Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.4.7 Nordic Countries Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.4.8 Benelux Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Targeted Therapy for Breast Cancer Revenue, 2018-2029
6.5.2 China Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.5.3 Japan Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.5.4 South Korea Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.5.5 Southeast Asia Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.5.6 India Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Targeted Therapy for Breast Cancer Revenue, 2018-2029
6.6.2 Brazil Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.6.3 Argentina Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Targeted Therapy for Breast Cancer Revenue, 2018-2029
6.7.2 Turkey Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.7.3 Israel Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.7.4 Saudi Arabia Targeted Therapy for Breast Cancer Market Size, 2018-2029
6.7.5 UAE Targeted Therapy for Breast Cancer Market Size, 2018-2029
7 Targeted Therapy for Breast Cancer Companies Profiles
7.1 Eli Lilly and Company
7.1.1 Eli Lilly and Company Company Summary
7.1.2 Eli Lilly and Company Business Overview
7.1.3 Eli Lilly and Company Targeted Therapy for Breast Cancer Major Product Offerings
7.1.4 Eli Lilly and Company Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.1.5 Eli Lilly and Company Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche Targeted Therapy for Breast Cancer Major Product Offerings
7.2.4 Roche Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.2.5 Roche Key News & Latest Developments
7.3 Merck & Co.
7.3.1 Merck & Co. Company Summary
7.3.2 Merck & Co. Business Overview
7.3.3 Merck & Co. Targeted Therapy for Breast Cancer Major Product Offerings
7.3.4 Merck & Co. Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.3.5 Merck & Co. Key News & Latest Developments
7.4 Novartis
7.4.1 Novartis Company Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Targeted Therapy for Breast Cancer Major Product Offerings
7.4.4 Novartis Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.4.5 Novartis Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Targeted Therapy for Breast Cancer Major Product Offerings
7.5.4 Pfizer Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Merck KGaA
7.6.1 Merck KGaA Company Summary
7.6.2 Merck KGaA Business Overview
7.6.3 Merck KGaA Targeted Therapy for Breast Cancer Major Product Offerings
7.6.4 Merck KGaA Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.6.5 Merck KGaA Key News & Latest Developments
7.7 Astellas
7.7.1 Astellas Company Summary
7.7.2 Astellas Business Overview
7.7.3 Astellas Targeted Therapy for Breast Cancer Major Product Offerings
7.7.4 Astellas Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.7.5 Astellas Key News & Latest Developments
7.8 Janssen Biotech
7.8.1 Janssen Biotech Company Summary
7.8.2 Janssen Biotech Business Overview
7.8.3 Janssen Biotech Targeted Therapy for Breast Cancer Major Product Offerings
7.8.4 Janssen Biotech Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.8.5 Janssen Biotech Key News & Latest Developments
7.9 Bristol-Myers Squibb
7.9.1 Bristol-Myers Squibb Company Summary
7.9.2 Bristol-Myers Squibb Business Overview
7.9.3 Bristol-Myers Squibb Targeted Therapy for Breast Cancer Major Product Offerings
7.9.4 Bristol-Myers Squibb Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.9.5 Bristol-Myers Squibb Key News & Latest Developments
7.10 Gilead Sciences
7.10.1 Gilead Sciences Company Summary
7.10.2 Gilead Sciences Business Overview
7.10.3 Gilead Sciences Targeted Therapy for Breast Cancer Major Product Offerings
7.10.4 Gilead Sciences Targeted Therapy for Breast Cancer Revenue in Global Market (2018-2023)
7.10.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Targeted Therapy for Breast Cancer Market Opportunities & Trends in Global Market
Table 2. Targeted Therapy for Breast Cancer Market Drivers in Global Market
Table 3. Targeted Therapy for Breast Cancer Market Restraints in Global Market
Table 4. Key Players of Targeted Therapy for Breast Cancer in Global Market
Table 5. Top Targeted Therapy for Breast Cancer Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Targeted Therapy for Breast Cancer Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Targeted Therapy for Breast Cancer Revenue Share by Companies, 2018-2023
Table 8. Global Companies Targeted Therapy for Breast Cancer Product Type
Table 9. List of Global Tier 1 Targeted Therapy for Breast Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Targeted Therapy for Breast Cancer Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Targeted Therapy for Breast Cancer Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Targeted Therapy for Breast Cancer Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Targeted Therapy for Breast Cancer Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Targeted Therapy for Breast Cancer Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Targeted Therapy for Breast Cancer Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Targeted Therapy for Breast Cancer Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2024-2029
Table 30. Eli Lilly and Company Company Summary
Table 31. Eli Lilly and Company Targeted Therapy for Breast Cancer Product Offerings
Table 32. Eli Lilly and Company Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 33. Eli Lilly and Company Key News & Latest Developments
Table 34. Roche Company Summary
Table 35. Roche Targeted Therapy for Breast Cancer Product Offerings
Table 36. Roche Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 37. Roche Key News & Latest Developments
Table 38. Merck & Co. Company Summary
Table 39. Merck & Co. Targeted Therapy for Breast Cancer Product Offerings
Table 40. Merck & Co. Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 41. Merck & Co. Key News & Latest Developments
Table 42. Novartis Company Summary
Table 43. Novartis Targeted Therapy for Breast Cancer Product Offerings
Table 44. Novartis Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 45. Novartis Key News & Latest Developments
Table 46. Pfizer Company Summary
Table 47. Pfizer Targeted Therapy for Breast Cancer Product Offerings
Table 48. Pfizer Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 49. Pfizer Key News & Latest Developments
Table 50. Merck KGaA Company Summary
Table 51. Merck KGaA Targeted Therapy for Breast Cancer Product Offerings
Table 52. Merck KGaA Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 53. Merck KGaA Key News & Latest Developments
Table 54. Astellas Company Summary
Table 55. Astellas Targeted Therapy for Breast Cancer Product Offerings
Table 56. Astellas Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 57. Astellas Key News & Latest Developments
Table 58. Janssen Biotech Company Summary
Table 59. Janssen Biotech Targeted Therapy for Breast Cancer Product Offerings
Table 60. Janssen Biotech Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 61. Janssen Biotech Key News & Latest Developments
Table 62. Bristol-Myers Squibb Company Summary
Table 63. Bristol-Myers Squibb Targeted Therapy for Breast Cancer Product Offerings
Table 64. Bristol-Myers Squibb Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 65. Bristol-Myers Squibb Key News & Latest Developments
Table 66. Gilead Sciences Company Summary
Table 67. Gilead Sciences Targeted Therapy for Breast Cancer Product Offerings
Table 68. Gilead Sciences Targeted Therapy for Breast Cancer Revenue (US$, Mn) & (2018-2023)
Table 69. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Targeted Therapy for Breast Cancer Segment by Type in 2022
Figure 2. Targeted Therapy for Breast Cancer Segment by Application in 2022
Figure 3. Global Targeted Therapy for Breast Cancer Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Targeted Therapy for Breast Cancer Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Targeted Therapy for Breast Cancer Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Targeted Therapy for Breast Cancer Revenue in 2022
Figure 8. By Type - Global Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 9. By Application - Global Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 10. By Type - Global Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 12. By Application - Global Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 14. By Region - Global Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 15. By Country - North America Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 16. US Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 20. Germany Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 21. France Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 28. China Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 32. India Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 34. Brazil Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Targeted Therapy for Breast Cancer Revenue Market Share, 2018-2029
Figure 37. Turkey Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Targeted Therapy for Breast Cancer Revenue, (US$, Mn), 2018-2029
Figure 41. Eli Lilly and Company Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Roche Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Merck & Co. Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Novartis Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Pfizer Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Merck KGaA Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Astellas Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Janssen Biotech Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Bristol-Myers Squibb Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Gilead Sciences Targeted Therapy for Breast Cancer Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

※参考情報

乳がん標的療法は、乳がんの治療において特定の分子や遺伝子を標的とする治療法です。このアプローチは、従来の化学療法や放射線療法とは異なり、がん細胞の成長や生存に関与する特定のメカニズムに対して作用します。標的療法は、より効果的かつ副作用の少ない治療選択肢として注目されており、個々の患者のがんの特徴に基づいた個別化医療の一環として位置付けられています。

まず、乳がんの生物学的特性を理解することが重要です。乳がんは非常に多様で、その進行や反応は患者ごとに異なります。がん細胞は、特定の遺伝子変異や異常なタンパク質の発現を示すことが多く、こうした特徴が標的療法の開発に寄与しています。例えば、HER2（ヒト上皮成長因子受容体2）は、特定のタイプの乳がんにおいて過剰に発現することが知られており、この受容体を標的とする治療が有効とされています。

標的療法の特徴としては、まずその選択性が挙げられます。がん細胞特有の標的にアプローチすることで、正常細胞への影響を最小限に抑えることが可能です。これにより、従来の治療法では一般的に見られる副作用を軽減することが期待されます。また、標的療法は通常、分子標的薬やモノクローナル抗体を用いて実施されます。これらの薬剤は、具体的にはタンパク質の機能を阻害したり、がん細胞の増殖を促進するシグナル伝達経路を遮断することを目的としています。

主に利用される標的療法の種類には、ホルモン療法、HER2標的療法、さまざまなキナーゼ阻害剤が含まれます。ホルモン療法は、エストロゲンやプロゲステロンに依存する乳がんに対して行われ、例えばタモキシフェンやアロマターゼ阻害剤が用いられます。HER2標的療法では、トラスツズマブ（ハーセプチン）などが使われ、HER2陽性の乳がん患者に効果を示します。

また、新しい治療法として、免疫療法も標的療法の一環として注目されています。免疫療法は、患者自身の免疫系を活性化し、がん細胞を攻撃させることを目的としています。特に、PD-1やPD-L1を標的とする治療薬は、進行した乳がんに対しても良好な成果を上げています。

標的療法の応用は、以下のような点でも進展しています。まず、バイオマーカーの利用です。乳がん患者に対する治療においては、腫瘍の分子特性や遺伝子変異を解析し、患者個々の特性に合った治療法を選択することが重要です。例えば、遺伝子パネルを用いた解析によって、どの標的療法が有効であるかを判断することができます。これにより、効果的な治療法を迅速に選択することが可能になります。

さらに、標的療法の進展を支える技術として、次世代シーケンシング（NGS）が挙げられます。NGSを用いることで、腫瘍の遺伝子情報を網羅的に解析でき、患者に適した標的療法の選択を助けることができます。この技術の発展により、乳がんの治療はますます個別化され、患者に最適な治療を提供することが可能になっています。

しかしながら、乳がん標的療法にはいくつかの課題も存在します。治療に対する耐性の発現がその一例です。初期の段階では良好な効果を示していても、がん細胞が適応し、治療に対して抵抗性を示すことがあります。これに対処するためには、新しい薬剤の開発や、治療法の組み合わせが求められます。

さらに、標的療法を選択する際には、患者の全体的な健康状態や、他の併存疾患なども考慮する必要があります。治療法の選択は、単にがんの特性だけでなく、患者のライフスタイルや希望にも影響されるため、医師と患者の間での十分なコミュニケーションが重要です。

総じて、乳がん標的療法は、今後ますます進化を続ける分野であるといえるでしょう。新たな研究や技術の進展が、乳がん治療の未来を切り開くことを期待しつつ、患者への最適な治療アプローチが引き続き模索されていく必要があります。個別化医療の進展により、より多くの患者がより効果的な治療を受けられる日が来ることを願ってやみません。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 乳がん標的療法の世界市場見通し2023年-2029年(Targeted Therapy for Breast Cancer Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

乳がん標的療法の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp